Navigation Links
3-V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for the Study of Liver Disease Annual Meeting 2012
Date:11/10/2012

th IC50s in the 5-50nM range;
  • Inhibitors have demonstrated excellent exposure and low toxicity in rodents associated with prolonged in vivo suppression of FASN;
  • Antiviral activity against wild-type Genotype 1a, 1b and 2a replicons; and
  • Antiviral activity against mutant HCV replicons resistant to NS3, NS4b, NS5a and NS5b inhibitors.
  • 3-V's FASN inhibitors are a chemically diverse set of potent, specific, reversible molecules with an excellent range of pharmaceutical properties.  The company has filed multiple worldwide patent applications covering these inhibitors.  3-V's HCV program is on track for an IND in the first quarter of 2013 and the company anticipates clinical proof-of-concept data by year-end 2013.

    Data describing 3-V's FASN inhibitor preclinical activity will be presented by Dr. Kemble during Sunday's HCV Therapy: Preclinical and Early Clinical Development parallel session at 5:30 pm in a talk titled: "Potent Hepatitis C Antiviral Activity By Inhibiting Fatty Acid Synthase" (Abstract #88).  A poster, "TVB-2640, a Novel Anti-HCV Agent, Safely Causes Sustained Host-Target Inhibition in Vivo" (Abstract #1876), describing mechanism and activity for one of 3-V's compounds will be presented on Tuesday, November 13 during the HCV Therapy: Preclinical and Early Clinical Development poster session from 8:00 a.m. to 12:00 p.m.

    About FASN
    FASN is a cellular enzyme implicated in HCV replication and several cancers.  First-generation FASN inhibitors have shown preclinical benefits in a variety of viral infections, including HCV, as well as in models of pancreatic, prostatic, breast and colorectal tumors, but their development has been hindered by poor bioavailability and systemic tolerability.  3-V has discovered and is advancing proprietary FASN inhibitors with pharmaceutical properties that overcome the shortcomings of earlier generations of inhibitors, and ha
    '/>"/>

    SOURCE 3-V Biosciences, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related medicine technology :

    1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
    2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
    3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
    4. Neurocrine Biosciences Reports First Quarter 2012 Results
    5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
    6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
    7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
    8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
    9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
    10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
    11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2014)... MURRAY HILL and NEW PROVIDENCE, ... management and engineering professionals are invited to meet with ... Conference and Technical Exhibition to be held at McCormick ... August 3-6. "Hospitals demand nothing less ... said Mark Sanda , Linde,s Healthcare Segment manager. ...
    (Date:7/28/2014)... July 28, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... Quarter 2014 Financial Results and Highlights Conference CallWhen:Monday, August ... www.isispharm.com How:Live on the Internet. Simply log onto ... participate during the live event, a replay of the ... www.isispharm.com . ABOUT ISIS PHARMACEUTICALS, INC. ...
    (Date:7/28/2014)... HILDEN , Germany ... 2014 , ... Begleitdiagnostikums, das auf Basis genomischer Daten aus Plasmaproben ... mit nicht-kleinzelligem Lungenkrebs eingesetzt werden kann  ... zugelassenem  therascreen   EGFR Kit und soll auf Rotor-Gene ...
    Breaking Medicine Technology:Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7
    ... , , ... use of stem cells in the treatment of heart failure, ... physicians have performed the world,s first phase-one FDA-approved clinical trial ... The clinical trial is being conducted by a team of ...
    ... , SAN MATEO, Calif., July 24 ... the preliminary results of a short-term clinical study (Study ... following pretreatment with an FDA-approved topical anesthetic. As part ... U.S. Food and Drug Administration (FDA) requested the study ...
    Cached Medicine Technology:NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 2NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 3NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 4
    (Date:7/28/2014)... Top Northridge dentist , Dr. Farshid Ariz, is ... new dentist can be an intimidating experience. Many people struggle ... and worry about how they will connect with a new ... concerns and dental needs and works to ensure that each ... special coupon can help patients get the treatments they need ...
    (Date:7/28/2014)... Freeonlinelifeinsuranceleads.com has released a new blog ... insurance quotes. , Comparing life insurance quotes can help ... costs. Finding affordable coverage is easier online by visiting ... agencies and displays them on a single web page. ... find cheaper coverage, but they can also learn more ...
    (Date:7/28/2014)... (HealthDay News) -- Following a healthy lifestyle may help ... issues, a new study indicates. Researchers suggested that ... should be educated about how their diet ... future. "These findings are important because they indicate ... have the opportunity to influence their own health outcomes," ...
    (Date:7/28/2014)... Nevada (PRWEB) July 28, 2014 Mahendra ... Trivedi, hosted the Trivedi Online Workshop ‘Consciousness is Power’ ... PM (EST). During this workshop, participants from all over ... importance of making a deeper connection to their inner ... the participants explored the various advantages of raising consciousness ...
    (Date:7/28/2014)... 28, 2014 Alta Resources , ... (BPO) for Fortune 500 brands, announced today that it ... locations in Wisconsin, California, Florida and the Philippines. More ... its Fort Myers campus, and the company announced that ... is to support several health-insurance clients, which have seasonal ...
    Breaking Medicine News(10 mins):Health News:Northridge Dentist, Dr. Farshid Ariz, is Now Offering a $100 Coupon for New Patients 2Health News:Comparing Life Insurance Quotes Online Offers 3 Important Advantages! 2Health News:Healthy Habits May Help Childhood Cancer Survivors Avoid Chronic Ills 2Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 2Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 3Health News:Alta Resources To Fill Approximately 1,200 Positions In Fort Myers 2Health News:Alta Resources To Fill Approximately 1,200 Positions In Fort Myers 3Health News:Alta Resources To Fill Approximately 1,200 Positions In Fort Myers 4
    ... Hospitals (UH) Case Medical Center is conducting the first ... "heat therapy" or local radiofrequency energy to treat premature ... to the energy produced by radio waves directed with ... a nerve. Premature ejaculation (PE) affects 20 percent ...
    ... Research Institute (LRI) today announced the award of 12 ... drive innovation and discover novel approaches to understand and ... diseases lupus. Awarded for the highest-ranked ... topics and multi-disciplinary approaches that mirror the heterogeneity and ...
    ... Institute (GHI) and Inserm (Institut National de la Sant ... for biomedical research) has discovered that a class of ... in cancer cells also kills the parasite that causes ... new strategy for combating this deadly disease. The ...
    ... leg ulcers is good quality nursing care and the ... University of Leeds has shown that ultrasound therapy does nothing ... contrary to what had been expected. Traditional methods of nursing ... as well, the authors conclude. "The ,healing energy, of ...
    ... might be required for maximum anti-tumor activity when ... studies by Vanderbilt-Ingram Cancer Center (VICC) investigators. The ... Proceedings of the National Academy of Sciences ... HER3 receptor limits the effectiveness of two classes ...
    ... An analysis conducted by Ohio State University cancer ... to the treatment of patients with advanced ovarian cancer ... value of various clinical strategies will be published online ... , The researchers performed a cost-effectiveness analysis looking at ...
    Cached Medicine News:Health News:University Hospitals Case Medical Center testing innovative 'heat therapy' for premature ejaculation 2Health News:LRI awards wide-ranging research grants to drive next generation of scientific discovery in lupus 2Health News:LRI awards wide-ranging research grants to drive next generation of scientific discovery in lupus 3Health News:LRI awards wide-ranging research grants to drive next generation of scientific discovery in lupus 4Health News:Malaria's weakest link 2Health News:Laughter really is the best medicine (for leg ulcers) 2Health News:Hit multiple targets for maximum benefit in HER2-positive breast cancer, studies suggest 2Health News:Ohio State study: Targeted ovarian cancer therapy not cost-effective 2Health News:Ohio State study: Targeted ovarian cancer therapy not cost-effective 3
    The ABL77 is always ready to use. No manual cassette preparation or calibration necessary prior to testing. Portable with battery. For both high and low volume testing....
    348 is fully automated blood gas systems offering a cost-effective solution for critical care testing in settings with low to medium workloads....
    The AVL Omni modular system is a complete blood gas solution designed for high-volume critical care use, with customized test combinations, minimum intervention and flexibility....
    ... optimal combination of performance and rapid, ... mL swinging bucket rotor. DiscoveryTMM120 SE ... to 8.3 ml, with a small ... quiet operation, rotor imbalance detection, thermo-electric ...
    Medicine Products: